ROYALTY PHARMA OA DL-0001
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabete… Read more
ROYALTY PHARMA OA DL-0001 (RPD) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ROYALTY PHARMA OA DL-0001 (RPD) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ROYALTY PHARMA OA DL-0001 - Net Assets Trend (None–None)
This chart illustrates how ROYALTY PHARMA OA DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ROYALTY PHARMA OA DL-0001 (None–None)
The table below shows the annual net assets of ROYALTY PHARMA OA DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ROYALTY PHARMA OA DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ROYALTY PHARMA OA DL-0001 Competitors by Market Cap
The table below lists competitors of ROYALTY PHARMA OA DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Northern Star Resources Ltd
PINK:NESRF
|
$14.98 Billion |
|
Akamai Technologies Inc
NASDAQ:AKAM
|
$14.98 Billion |
|
Omnicom Group Inc
NYSE:OMC
|
$15.01 Billion |
|
JB Hunt Transport Services Inc
NASDAQ:JBHT
|
$15.02 Billion |
|
MACOM Technology Solutions Holdings Inc
NASDAQ:MTSI
|
$14.97 Billion |
|
XPENG INC. SP.ADS/2 CL.A
F:8XPA
|
$14.97 Billion |
|
Roivant Sciences Ltd
NASDAQ:ROIV
|
$14.92 Billion |
|
Shriram Finance Limited
NSE:SHRIRAMFIN
|
$14.92 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ROYALTY PHARMA OA DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ROYALTY PHARMA OA DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ROYALTY PHARMA OA DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ROYALTY PHARMA OA DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ROYALTY PHARMA OA DL-0001 (RPD) | €- | N/A | N/A | $14.98 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |